Salarius Pharmaceuticals Inc (SLRX)

NASDAQ
Currency in USD
0.7790
+0.0229(+3.03%)
Closed·
After Hours
0.7690-0.0100(-1.2837%)
·
SLRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SLRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.70550.8900
52 wk Range
0.45197.2000
Key Statistics
Edit
Prev. Close
0.7561
Open
0.89
Day's Range
0.7055-0.89
52 wk Range
0.4519-7.2
Volume
146.77K
Average Volume (3m)
1.21M
1-Year Change
-72.3%
Book Value / Share
0.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Salarius Pharmaceuticals Inc Company Profile

Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.

Compare SLRX to Peers and Sector

Metrics to compare
SLRX
Peers
Sector
Relationship
P/E Ratio
−0.3x−4.5x−0.5x
PEG Ratio
0.000.030.00
Price/Book
26.0x3.2x2.6x
Price / LTM Sales
-27.9x3.1x
Upside (Analyst Target)
-140.4%45.7%
Fair Value Upside
Unlock10.6%5.7%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-1.03 / -1.03
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SLRX Income Statement

People Also Watch

1.46
KLTO
+6.57%
1.2900
OP
+4.03%
2.310
VOR
-9.06%
2.94
RBNE
+5.38%

FAQ

What Stock Exchange Does Salarius Pharmaceuticals Trade On?

Salarius Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Salarius Pharmaceuticals?

The stock symbol for Salarius Pharmaceuticals is "SLRX."

What Is the Salarius Pharmaceuticals Market Cap?

As of today, Salarius Pharmaceuticals market cap is 1.61M.

What Is Salarius Pharmaceuticals's Earnings Per Share (TTM)?

The Salarius Pharmaceuticals EPS (TTM) is -4.47.

From a Technical Analysis Perspective, Is SLRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Salarius Pharmaceuticals Stock Split?

Salarius Pharmaceuticals has split 3 times.

How Many Employees Does Salarius Pharmaceuticals Have?

Salarius Pharmaceuticals has 2 employees.

What is the current trading status of Salarius Pharmaceuticals (SLRX)?

As of 10 Jul 2025, Salarius Pharmaceuticals (SLRX) is trading at a price of 0.78, with a previous close of 0.76. The stock has fluctuated within a day range of 0.71 to 0.89, while its 52-week range spans from 0.45 to 7.20.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.